•   Preliminary results of NATHALI-01 and updated results of BALLI-01 Phase I clinical studies presented at the American Society of Hematology (ASH) 65th Annual Meeting •   Execution of strategic collaboration and investment agreements with AstraZeneca •   Cécile Chartier, Ph.D., appointed as a director of the Cellectis' Board of Directors •   Drawdown of the second tranche of €15 million under the credit facility agreement entered into with the European Investment Bank (EIB) •   Cash position of $156 milli ...

This novel editing approach might unlock new strategies for the treatment of metabolic and neurological diseasesNon-viral circular ssDNA delivery associated to TALEN® gene editing allows high levels of gene insertion in long-term repopulating HSPCs NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ:  CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, will present first ...

NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new research paper in Molecular Therapy, demonstrating that TALEN-mediated intron editing of hematopoietic stem and progenitor cells (HSPCs) enables transgene expression restricted to the myeloid lineage. This approach could unlock new therapeutic avenues for ...

Cellectis SA (NASDAQ:CLLS) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Co-founder, CEO& Director Mark Frattini - Chief Medical Officer Bing Wang - CFO Conference Call Participants Dev Prasad - Jefferies Hartaj Singh - Oppenheimer Jack Allen - Robert W. Baird & Co. Silvan Tuerkcan - JMP Securities Whitney Watson - Goldman Sachs Operator Good morning, everyone, and welcome to the Cellectis Third Quarter 2023 Earnings ...

Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Currently, our cash and cash equivalents are held in bank accounts, money market funds, and fixed bank deposits, in each case primarily in France. The portion of cash and cash equivalents denominated in U.S. dollars is $44.5 million as of September 30, 2023. Historical Changes in Cash Flows The table below summarizes our sources and uses of cash For the ...

Exhibit 99.1 The unaudited condensed Consolidated Financial Statements for the three- and six-month periods ended June 30, 2023, included herein, have been prepared in accordance with International Accounting Standard 34 ("IAS 34")– Interim Financial Reporting as issued by the International Accounting Standards Board ("IASB"). The consolidated financial statements are presented in U.S. dollars. All references in this interim report to "$" and "U.S. dollars" mean U.S. dollars and all references to "€" and "e ...

Cellectis SA (NASDAQ:CLLS) Q2 2023 Earnings Conference Call August 5, 2023 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Co-Founder, CEO & Director Mark Frattini - SVP, Clinical Sciences & Chief Medical Officer Bing Wang - CFO Conference Call Participants Yigal Nochomovitz - Citigroup Gena Wang - Barclays Bank Yanan Zhu - Wells Fargo Anoumid Vaziri - Goldman Sachs Group Dev Prasad - Jefferies Hartaj Singh - Oppenheimer Jack Allen - Robert W. Baird Silvan Tuerkcan - J ...

Cellectis SA (NASDAQ:CLLS) Q1 2023 Earnings Conference Call May 5, 2023 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Co-Founder, CEO & Director Mark Frattini - SVP, Clinical Sciences & Chief Medical Officer Bing Wang - CFO Conference Call Participants Gena Wang - Barclays Bank Yigal Nochomovitz - Citigroup Anoumid Vaziri - Goldman Sachs Group Dev Prasad - Jefferies Hartaj Singh - Oppenheimer Jack Allen - Robert W. Baird & Co. Ingrid Gafanhao - Kempen Silvan Tuerkcan ...

Financial Performance - For the three-month period ended March 31, 2023, the net loss was $32.5 million, compared to a net loss of $34.8 million for the same period in 2022, representing a 6.5% improvement [9]. - Total comprehensive loss for the three-month period ended March 31, 2023, was $31.4 million, compared to a total comprehensive loss of $37.4 million for the same period in 2022, indicating a 16.5% reduction [9]. - Calyxt incurred a net loss of $5.4 million for the three months ended March 31, 2023, and used $2.0 million of cash for operating activities during the same period [338]. Cash Flow and Liquidity - Net cash flows used in operating activities for the three-month period ended March 31, 2023, were $28.3 million, an improvement from $36.6 million used in the same period in 2022, reflecting a 22.5% decrease in cash outflow [331]. - As of March 31, 2023, Cellectis, excluding Calyxt, had cash and cash equivalents of $83.5 million, sufficient to continue operations for at least twelve months [336]. - Cellectis expects cash flow from operations, government funding, and a €40.0 million finance contract with the European Investment Bank to support operations into the third quarter of 2024 [336]. - Calyxt has received $1.0 million of Interim Funding from Cibus as of March 31, 2023, with an additional $0.5 million received subsequently [340]. Going Concern and Regulatory Approval - Cellectis faces substantial doubt regarding Calyxt's ability to continue as a going concern for a period of 12 months or more from the filing date of its quarterly report [342]. - The company anticipates that it will not generate significant revenues from product sales until regulatory approval is obtained for its therapeutic product candidates [335]. Financial Reporting Adjustments - The company has made adjustments in its financial reporting to reflect discontinued operations, impacting the overall financial results presented [8].

Product Development - Cellectis will present updated preclinical data on its product candidate UCARTMUC1 for solid tumors at the AACR 2023, highlighting its potential for patients with high unmet medical needs[3] - The company developed multiplexed gene editing using TALEN® technology to enhance CAR T-cell efficacy while maintaining safety in hostile tumor microenvironments[4] - Cellectis is pioneering off-the-shelf, ready-to-use gene-edited CAR T-cells, leveraging over 22 years of experience in gene editing[5] - The therapeutic target MUC1 is overexpressed in a significant number of triple-negative breast cancer (TNBC) patients, making it a promising target for CAR T-cell therapy[8] - The presentation will explore the benefits of variable delivery routes and molecular armoring to improve the efficacy of MUC1-CAR T-cells[9] - Cellectis utilizes an allogeneic approach for CAR-T immunotherapies, aiming to address the challenges posed by the tumor microenvironment[5] - The company is committed to developing life-changing product candidates to treat diseases with unmet medical needs[5] Company Information - Cellectis' headquarters are located in Paris, France, with additional locations in New York and Raleigh, North Carolina[5] - The company is listed on both the Nasdaq Global Market (ticker: CLLS) and Euronext Growth (ticker: ALCLS)[5] Risks and Uncertainties - Forward-looking statements indicate potential risks and uncertainties related to product development and cash runway[6]